跳至主要内容
临床试验/NCT05506891
NCT05506891招募中2 期

Efficacy and Safety of Astragalus for Non-Motor Symptoms of α-Synucleinopathy:an Open-Label Self-Controlled Before-and-After Study

Fujian Medical University Union Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
40
试验地点
1
主要终点
Change from baseline mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) at 3 months.

研究概览

简要总结

α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. However, there is still a lack of research on the treatment for non-motor symptoms of α-synucleinopathy, especially autonomic dysfunctions such as orthostatic hypotension. Efficacy and safety of astragalus for non-motor symptoms of α-synucleinopathy will be assessed by an open-label self-controlled before-and-after study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with a clinical diagnosis of PD, MSA and DLB, with orthostatic hypotension.
  • Participants with cognitive disorder.
  • Adults signed informed consents.

排除标准

  • Patients with history of astragalus allergy.
  • Patients with secondary Parkinsonism that cannot be excluded.
  • Patients with diseases that may cause other types of hypotension or similar symptoms/signs because of hypotension
  • Patients with other medical conditions requiring treatments that may affect blood pressure.
  • Patients with other neurological disorders.
  • Patients with serious comorbidities and immune diseases.
  • Uncooperative patients.
  • Pregnant or lactating women.

研究组 & 干预措施

Astragalus group

Experimental

干预措施: Astragalus (Drug)

Physical therapy group

Active Comparator

干预措施: Physical therapy group (Behavioral)

结局指标

主要结局

Change from baseline mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) at 3 months.

时间窗: Baseline vs 3 months after treatment.

Mean arterial pressure was calculated as ⅓ pulse pressure + diastolic pressure.

次要结局

  • Change from baseline decumbent and orthostatic digit span (DDS) difference at 3months.(Baseline vs 3 months after treatment.)
  • Change from baseline HRV (ms) at 3months.(Baseline vs 3 months after treatment.)
  • Change from baseline HDS scores at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline CDR scores at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline HAS scores at 3 months.(Baseline vs 3 months after treatment.)
  • OH Questionnaire score(Baseline vs 3 months after treatment.)
  • Change from baseline decumbent and orthostatic character conversion (CDS) difference at 3months.(Baseline vs 3 months after treatment.)
  • Change from the baseline plasma α-synuclein levels (ng/ml) at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline ODI at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline Rate of change in ΔHR/ΔSBP at 3months.(Baseline vs 3 months after treatment.)
  • Change from baseline MoCA scores at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline RAVLT scores at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline NPI scores at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline Vic at 3 months.(Baseline vs 3 months after treatment.)
  • Change from baseline PAF (Hz) at 3 months.(Baseline vs 3 months after treatment.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验